rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Legend Biotech Corporation - American Depositary Shares

LEGN · Nasdaq

Health CareBiotechnologyNot moving yetSynthetic Biology / TechBio

LEGN stood above a rising 150-day average in 3 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 20.2% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 14
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$875K
Officials’ trades on record
0
Institutions holding
208 (+26)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 3 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$345K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months5
Buyers · sellers0 · 4
WhoDidSharesTraded
Corazon (Corsee) D. SandersDirectorsold27,370at $9.4629 Sep 2026filed 1 Oct 2026
Carlos E. SantosChief Financial Officersold5,430at $9.1421 Sep 2026filed 23 Sep 2026
Patrick John CaseyDirectorsold6,000at $14.8030 Jun 2026filed 2 Jul 2026
Ying HuangChief Executive Officersold5,566at $14.7825 Jun 2026filed 29 Jun 2026
Ying HuangChief Executive Officersold9,936at $8.7725 Mar 2026filed 27 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders208+26 on the quarter
New · exited56 · 29
Reported value$3.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202629,093,899$840.2M+3,397,159+13.2%
DEERFIELD MANAGEMENT COMPANY, L.P.added · filed 14 Aug 20268,137,638$235.0M+450,000+5.9%
MONTANOVA CAPITAL, LLCreduced · filed 14 Aug 20267,070,000$204.2M-511,029−6.7%
HHLR ADVISORS, LTD.unchanged · filed 14 Aug 20265,984,550$172.8M00.0%
BlackRock, Inc.added · filed 7 Aug 20264,726,534$136.5M+41,991+0.9%
WESTFIELD CAPITAL MANAGEMENT CO LPreduced · filed 12 Aug 20264,430,063$127.9M-1,333,412−23.1%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20263,662,315$105.8M+2,198,203+150.1%
Point72 Asset Management, L.P.reduced · filed 14 Aug 20263,076,124$88.8M-809,893−20.8%
Kynam Capital Management, LPadded · filed 14 Aug 20263,001,205$86.7M+1,424,910+90.4%
Assenagon Asset Management S.A.new · filed 8 Jul 20261,915,056$55.3M+1,915,056
31 Mar 2023 – 30 Jun 2026
136171205Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Corazon (Corsee) D. Sanders Company insiderDirector · last 29 Sep 20260 · 1
Darren Xiaohui Ji Company insiderDirector · last 24 Sep 20260 · 0
Li Mao Company insiderDirector · last 24 Sep 20260 · 0
Patrick John Casey Company insiderDirector · last 24 Sep 20260 · 1
Peter Salovey Company insiderDirector · last 24 Sep 20260 · 0
Tomas J. Heyman Company insiderDirector · last 24 Sep 20260 · 0
Carlos E. Santos Company insiderChief Financial Officer · last 21 Sep 20260 · 1
Ingrid Zhang Company insiderChief Executive Officer · last 15 Sep 20260 · 0
Alan Bash Company insiderInterim CEO · last 14 Aug 20260 · 0
Ying Huang Company insiderChief Executive Officer · last 30 Jun 20260 · 2

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 31 Dec 20250.7%

Analyst forecasts

No analyst forecasts yet.